Tridek-One

Novel Platform for modulating Vasculitis

Tridek-One develops first-in-class CD31 checkpoint agonists to restore the immune balance and treat auto-immune diseases.

CEO  Laurence de Schoulepnikoff

tridekone.com

Advent Contact   Fraser Murray

Advent invested in the Seed round in 2018.
Private Companies